David E. Wazer
Brown University
300 Papers
3.6K Citations
David E. Wazer is an academic researcher from Brown University. The author has contributed to research in topics: Breast cancer & Radiation therapy. The author has an hindex of 58, co-authored 289 publications. Previous affiliations of David E. Wazer include VCU Medical Center & Tufts Medical Center.
Chat about Author
Papers
•Journal Article
E7 Protein of Human Papilloma Virus-16 Induces Degradation of Retinoblastoma Protein through the Ubiquitin-Proteasome Pathway
TL;DR: Evidence is provided for HPV-16 E7-induced enhanced degradation of Rb protein via a ubiquitin-proteasome pathway and a second mechanism of oncogenic transformation by E7 is suggested, in addition to its previously identified ability to sequester Rb from E2F.
Factors influencing cosmetic outcome and complication risk after conservative surgery and radiotherapy for early-stage breast carcinoma.
David E. Wazer,Thomas A. DiPetrillo,Rupert Schmidt-Ullrich,L Weld,Thomas J. Smith,D J Marchant,Nicholas J. Robert +6 more
TL;DR: Optimal cosmesis and minimal complication risk require careful attention to the technical details of surgery and radiotherapy.
357
Immortalization of distinct human mammary epithelial cell types by human papilloma virus 16 E6 or E7.
TL;DR: Identification of MECs with distinct susceptibilities to p53- and Rb-targeting human papillomavirus oncogenes raises the possibility that these cells may serve as precursors for different forms of breast cancer.
203
•Journal Article
The role for NES1 serine protease as a novel tumor suppressor.
TL;DR: It is demonstrated that stable expression of NES1 in the NES1-negative MDA-MB-231 breast cancer cell line suppressed the oncogenicity as revealed by inhibition of the anchorage-independent growth and tumor formation in nude mice.
194
Accelerated partial breast irradiation: An analysis of variables associated with late toxicity and long-term cosmetic outcome after high-dose-rate interstitial brachytherapy
David E. Wazer,David E. Wazer,Seth A. Kaufman,Seth A. Kaufman,Laurie W. Cuttino,Thomas A. DiPetrillo,Thomas A. DiPetrillo,Douglas W. Arthur +7 more
TL;DR: The use of adriamycin-based chemotherapy after APBI was found to be associated with a significant increase in the incidence of higher-grade skin toxicity and a higher risk of fat necrosis and suboptimal cosmetic outcome.
192